We narrowed to 1,077 results for: plasmid

#20071-AAV1

Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Leopoldo et al Nature. 2009 Jan 18.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#105921-AAV2

Ready-to-use AAV2 particles produced from pAAV-CBh-mKate2-IRES-MCS (WT-WT) (#105921). In addition to the viral particles, you will also receive purified pAAV-CBh-mKate2-IRES-MCS (WT-WT) plasmid DNA. Control mKate2 expression AAV with two wild-type ITR sequences. These AAV preparations are suitable purity for injection into animals.

Marcella Patrick

Nov. 13, 2018

Academic Institutions and Nonprofits only

#52962-LV

Ready-to-use Lentiviral Prep particles produced from lentiCas9-Blast (#52962). In addition to the viral particles, you will also receive purified lentiCas9-Blast plasmid DNA. Lentiviral particles carrying Cas9 and blasticidin resistance. This virus is used to make stable cell lines expressing Cas9.

Feng Zhang

Sanjana et al Nat Methods. 2014 Aug;11(8):783-4. doi:

July 14, 2016

Academic Institutions and Nonprofits only

#58880-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

Oct. 13, 2017

Academic Institutions and Nonprofits only

#124651-AAV9

Ready-to-use AAV9 particles produced from pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 (#124651). In addition to the viral particles, you will also receive purified pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 plasmid DNA. CamKIIa-driven expression of ChrimsonR fused to mScarlet fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Aug. 27, 2019

Academic Institutions and Nonprofits only

#214147-AAV5

Ready-to-use AAV5 particles produced from pAAV-hIBA1a-GFP-miR124T (#214147). In addition to the viral particles, you will also receive purified pAAV-hIBA1a-GFP-miR124T plasmid DNA. hIBA1a-driven and miR124T-targeted for microglial inhibition of GFP. These AAV preparations are suitable purity for injection into animals.

Chun-Li Zhang

Serrano et al iScience. 2024 Aug 12;27(9):110706. doi:

Sept. 22, 2025

Academic Institutions and Nonprofits only

#124651-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 (#124651). In addition to the viral particles, you will also receive purified pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 plasmid DNA. CamKIIa-driven expression of ChrimsonR fused to mScarlet fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Aug. 7, 2025

Academic Institutions and Nonprofits only

#173044-AAV2

Ready-to-use AAV2 particles produced from AAV-Camk2-NES-Twitch-GR (#173044). In addition to the viral particles, you will also receive purified AAV-Camk2-NES-Twitch-GR plasmid DNA. CamKII-driven expression of TnC-based calcium biosensor NES-Twitch-GR. These AAV preparations are suitable purity for injection into animals.

Yiyang Gong

Zhang et al Commun Biol. 2021 Jul 29;4(1):924. doi:

Nov. 13, 2025

Academic Institutions and Nonprofits only

#196410-AAV5

Ready-to-use AAV5 particles produced from AAV-GfaABC1D-Cre-4x6T (#196410). In addition to the viral particles, you will also receive purified AAV-GfaABC1D-Cre-4x6T plasmid DNA. GfaABC1D driven expression of Cre recombinase in astrocytes. These AAV preparations are suitable purity for injection into animals.

Stanley Thomas Carmichael

Gleichman et al Nat Commun. 2023 Nov 16;14(1):7426. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#52536-AAV1

Ready-to-use AAV1 particles produced from rAAV-CAG::FLEX-rev:: hM4D-2a-GFP (#52536). In addition to the viral particles, you will also receive purified rAAV-CAG::FLEX-rev:: hM4D-2a-GFP plasmid DNA. CAG driven, Cre-dependent expression of hM4D and GFP. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al Nature. 2012 Aug 9;488(7410):172-7. doi:

Dec. 18, 2024

Academic Institutions and Nonprofits only

#26968-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

March 30, 2018

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#26968-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 20, 2018

Academic Institutions and Nonprofits only

#100896-AAV5

Ready-to-use AAV5 particles produced from pAAV.GFA104.PI.eGFP.WPRE.bGH (#100896). In addition to the viral particles, you will also receive purified pAAV.GFA104.PI.eGFP.WPRE.bGH plasmid DNA. GFA104-driven eGFP expression. These AAV preparations are suitable purity for injection into animals.

Philip Haydon

Ortinski et al Nat Neurosci. 2010 May;13(5):584-91. doi

April 6, 2018

Academic Institutions and Nonprofits only

#92207-AAV1

Ready-to-use AAV1 particles produced from TRE-ChrimsonR-mCherry (#92207). In addition to the viral particles, you will also receive purified TRE-ChrimsonR-mCherry plasmid DNA. TRE-driven ChrimsonR-mCherry expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Alice Ting

Wang et al Nat Biotechnol. 2017 Jun 26. doi: 10.103

Nov. 13, 2025

Academic Institutions and Nonprofits only

#174112-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-mitoGFP-DIO (#174112). In addition to the viral particles, you will also receive purified pAAV-EF1a-mitoGFP-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GFP. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#197200-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-emiRFP670 (#197200). In addition to the viral particles, you will also receive purified pAAV-CAG-emiRFP670 plasmid DNA. CAG-driven expression of emiRFP670. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhang et al Nat Methods. 2023 Sep 4. doi: 10.1038/s4

Feb. 7, 2025

Academic Institutions and Nonprofits only

#17446-LV

Ready-to-use Lentiviral Prep particles produced from pLenti CMV GFP Hygro (656-4) (#17446). In addition to the viral particles, you will also receive purified pLenti CMV GFP Hygro (656-4) plasmid DNA. Lentiviral particles carrying the GFP and hygromycin resistance.

Eric Campeau, Paul Kaufman

Campeau et al PLoS One. 2009 Aug 6;4(8):e6529.

Oct. 6, 2020

Academic Institutions and Nonprofits only

#124603-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 (#124603). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-ChrimsonR-mRuby2-KV2.1-WPRE-SV40 plasmid DNA. EF1a-driven, Cre-dependent expression of ChrimsonR fused to mRuby2 fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Sept. 26, 2019

Academic Institutions and Nonprofits only

#44332-AAV5

Ready-to-use AAV5 particles produced from pZac2.1 gfaABC1D-tdTomato (#44332). In addition to the viral particles, you will also receive purified pZac2.1 gfaABC1D-tdTomato plasmid DNA. GfaABC1D-driven tdTomato expression control. These AAV preparations are suitable purity for injection into animals.

Baljit Khakh

Shigetomi et al J Gen Physiol. 2013 Apr 15.

April 12, 2018

Academic Institutions and Nonprofits only